Work

Safety of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (pembro, anti-PD-1) monoclonal antibody, in men with metastatic castration-resistant prostate cancer (mCRPC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.6_suppl.140

Authors: Rahul Raj Aggarwal, Dan Costin, Vincent J. O'Neill, Cedric R Burg, Diane I. Healey, Johann S. De Bono, Jingsong Zhang, Eric Jay Small

Institutions: UCSF Helen Diller Family Comprehensive Cancer Center, White Plains Hospital, BioXcel Therapeutics, Inc. (United States), Royal Marsden NHS Foundation Trust, Moffitt Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3007454963

Cites:

Cited by: 3

Related to: 10